Maven Clinic Launches Nationwide DTC Platform Integrating GLP-1 and Hormone Care

New updates have been reported about Maven Clinic.

Maven Clinic has launched a nationwide direct-to-consumer platform that links GLP-1 and hormone therapies with its digital network of women’s health providers, expanding access beyond its traditional employer and health-plan channels. The move positions Maven to monetize growing consumer demand for weight management and hormone care while differentiating through integrated, longitudinal support rather than one-off prescribing.

The launch is underpinned by new research from the Maven Clinical Research Institute, which surveyed 1,538 U.S. women ages 30 to 60 and 520 providers and found 37% of women on GLP-1 or hormone medications reported limited or no follow-up care, and 41% of providers lack time to support patients after prescribing GLP-1s. Maven’s findings also show only 19% of women say hormonal factors are consistently considered in reproductive care, and nearly half have turned to non-clinical sources, underscoring a structural gap that Maven aims to capture with its full-stack virtual model.

The new platform offers GLP-1 care for women that combines prescription access with ongoing clinical oversight, hormone support, nutrition and strength guidance, all tailored to reproductive history and life stage. It also introduces comprehensive perimenopause and menopause programs and integrates on-demand access to more than 30 specialties, including OB-GYN, mental health and nutrition, in a single, connected care experience designed to reduce fragmentation.

Founder and CEO Kate Ryder framed the strategy as connecting metabolic, hormonal, mental and reproductive health in one continuum of care, addressing a market where women’s health has been “consumerized” faster than it has been clinically integrated. For payers and employers, the expansion broadens Maven’s value proposition beyond its existing 2,300 enterprise clients and 28 million covered lives, while for Maven it opens a direct revenue stream from consumers seeking GLP-1 and hormone therapies with clinically guided oversight.

With more than $425 million raised from leading healthcare investors, Maven is effectively leveraging its enterprise infrastructure to enter a high-growth, cash-pay segment where GLP-1 demand and midlife women’s health needs are expanding rapidly. The consumer launch could enhance utilization of Maven’s provider network, strengthen data assets through broader engagement and create cross-sell opportunities between enterprise-sponsored members and direct users, though it also exposes the company to regulatory scrutiny and competition from GLP-1-focused telehealth platforms and traditional health systems.